Business Context and Reporting Period
This Form 8-K Current Report, dated August 2, 2018, concerns BeiGene, Ltd. (Note: The request metadata referenced "Beone Medicines Ltd.", but the filing text identifies the registrant as BeiGene, Ltd.). The report details the pricing of an underwritten global offering of ordinary shares and the entry into a material definitive agreement with international underwriters.
Key Financial Metrics
- Offering Size: 65,600,000 ordinary shares initially offered.
- Offering Price: HK$108.00 per share (approximately US$13.76 per share based on an exchange rate of HK$7.8478 to US$1.00).
- Gross Proceeds: Approximately HK$7.08 billion (approximately US$903 million) before deducting underwriting discounts, commissions, and offering expenses.
- Over-Allotment Option: A 30-day option granted to joint global coordinators to purchase up to 9,840,000 additional shares.
- Listing Status: Shares expected to begin trading on the Main Board of The Stock Exchange of Hong Kong Limited (SEHK) on August 8, 2018, under stock code "06160". The company will be dual-listed with American Depositary Shares (ADSs) on NASDAQ.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. Those figures are referenced as being contained in prior filings (Form 10-K and 10-Q).
Material Changes
The primary material change is the execution of the International Underwriting Agreement and the pricing of the global offering. This transaction transitions the company to a dual-listed status on the SEHK and NASDAQ. The filing does not report changes to prior period financial performance metrics.
Guidance, Outlook, and Risks
Outlook and Use of Proceeds: The company expects the offering to close on August 8, 2018, subject to customary conditions. The filing references forward-looking statements regarding the use of proceeds and the potential approval and commercialization of core product candidates, though specific details on the use of proceeds are not enumerated in this text.
Risks and Contingencies:
- The offering is subject to market conditions and closing conditions; there is no assurance it will be completed.
- Offering expenses may exceed planned amounts.
- Failure by the company or underwriters to perform obligations under the International Underwriting Agreement.
- General risks associated with the company's business as detailed in its Annual Report on Form 10-K for the year ended December 31, 2017, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.
Investor Verification Checklist
- Verify the final closing date of the offering and whether the 30-day over-allotment option was exercised.
- Review the full text of the International Underwriting Agreement (Exhibit 1.1) for specific indemnification terms and covenants.
- Consult the company's Form 10-K (2017) and Form 10-Q (Q1 2018) for historical financial performance, debt levels, and liquidity positions not included in this 8-K.
- Confirm the actual net proceeds after deducting underwriting discounts and offering expenses.
- Monitor the trading debut on the SEHK on August 8, 2018, under stock code "06160".